Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: munderi p. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. Crook AM, et al. Among authors: munderi p. BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7. BMC Med. 2016. PMID: 27004529 Free PMC article. Clinical Trial.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.
Mandima P, Baltrusaitis K, Montepiedra G, Aaron L, Mathad J, Onyango-Makumbi C, Nyati M, Ngocho J, Chareka G, Ponatshego P, Masheto G, McCarthy K, Jean-Philippe P, Gupta A, Stranix-Chibanda L; IMPAACT P1078 T. B. APPRISE study team. Mandima P, et al. BMC Pregnancy Childbirth. 2023 Jan 17;23(1):34. doi: 10.1186/s12884-022-05341-3. BMC Pregnancy Childbirth. 2023. PMID: 36650479 Free PMC article. Clinical Trial.
The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan Africa.
Prendergast AJ, Szubert AJ, Pimundu G, Berejena C, Pala P, Shonhai A, Hunter P, Arrigoni FIF, Musiime V, Bwakura-Dangarembizi M, Musoke P, Poulsom H, Kihembo M, Munderi P, Gibb DM, Spyer MJ, Walker AS, Klein N; and the ARROW Trial Team. Prendergast AJ, et al. Among authors: munderi p. AIDS. 2021 Aug 1;35(10):1537-1548. doi: 10.1097/QAD.0000000000002916. AIDS. 2021. PMID: 34270487 Free PMC article.
Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.
Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, Salazar-Gonzalez JF, Salazar MG, Sanyu G, Lutalo T, Kabuga U, Ssewanyana I, Namatovu F, Namayanja G, Namale A, Raizes E, Kaggwa M, Namuwenge N, Kirungi W, Katongole-Mbidde E, Kaleebu P; Uganda HIV Drug Resistance Technical Working Group. Ssemwanga D, et al. J Antimicrob Chemother. 2020 May 1;75(5):1280-1289. doi: 10.1093/jac/dkz561. J Antimicrob Chemother. 2020. PMID: 32025714 Free PMC article.
Dyslipidemias and cardiovascular risk scores in urban and rural populations in north-western Tanzania and southern Uganda.
Kavishe B, Vanobberghen F, Katende D, Kapiga S, Munderi P, Baisley K, Biraro S, Mosha N, Mutungi G, Mghamba J, Hughes P, Smeeth L, Grosskurth H, Peck R. Kavishe B, et al. Among authors: munderi p. PLoS One. 2019 Dec 6;14(12):e0223189. doi: 10.1371/journal.pone.0223189. eCollection 2019. PLoS One. 2019. PMID: 31809516 Free PMC article.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Ross LL, Walker AS, Lou Y, Tenorio AR, Gibb DM, Double J, Gilks C, McCoig CC, Munderi P, Musoro G, Kityo CM, Grosskurth H, Hakim J, Mugyenyi PN, Cutrell A, Perger T, Shaefer MS. Ross LL, et al. Among authors: munderi p. PLoS One. 2019 Nov 14;14(11):e0225199. doi: 10.1371/journal.pone.0225199. eCollection 2019. PLoS One. 2019. PMID: 31725787 Free PMC article.
101 results